Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
4BIO Capital is a London-based venture capital firm founded to ensure access to potentially curative therapies for all patients. The firm focuses on the advanced therapies sector, specifically targeting early-stage companies that develop treatments for high unmet medical needs. 4BIO Capital operates primarily in Europe and the United Kingdom, emphasizing its commitment to addressing significant medical challenges.
The firm invests in various innovative areas, including cell and gene therapy, RNA-based therapy, targeted therapies, and microbiome-related treatments. Its team comprises experts with diverse backgrounds in medicine, finance, and academia, including several PhDs and industry veterans. Although specific fund sizes and portfolio counts are not disclosed, 4BIO Capital's mission is to support the growth of companies that can deliver transformative healthcare solutions.
4BIO Capital's investment strategy is centered on early-stage companies within the advanced therapies sector. The firm specifically seeks opportunities in cell therapy, gene therapy, RNA-based therapy, targeted therapies, and microbiome-related treatments. By focusing on these areas, 4BIO Capital aims to address significant medical and social needs, ensuring that innovative therapies reach patients who require them the most.
The firm operates at the pre-seed, seed, and seed-plus stages, allowing it to engage with startups at various points in their development. 4BIO Capital looks for high-quality, viable opportunities that align with its mission to support the advancement of healthcare solutions. This targeted approach enables the firm to make impactful investments that can lead to significant improvements in patient care.
4BIO Capital's portfolio includes notable companies that are making strides in the advanced therapies sector:
These companies exemplify 4BIO Capital's focus on supporting ventures that address high unmet medical needs through advanced therapies.
Philippe Fauchet OBE, Venture Partner, Japan - Philippe brings extensive experience in the biotech sector and has held various leadership roles in international firms.
Vasily Fedorin PhD, Chief Operating Officer - Vasily has a strong background in operational management and has previously worked in both academia and industry.
Andrew Kozlov MBA, Managing Partner - Andrew has a wealth of experience in venture capital and has led numerous successful investments in the healthcare sector.
Dima Kuzmin PhD, Managing Partner - Dima specializes in advanced therapies and has a strong academic background in biotechnology.
Edward McGill FCA, Financial Controller - Edward oversees financial operations and has a background in finance and accounting.
Alexander McKenna PhD, Investment Associate - Alexander focuses on evaluating investment opportunities in the biotech sector.
Kieran Mudryy LLB, Partner - Kieran has expertise in legal matters related to venture capital and investments.
Natalie Johnston PhD, Investment Principal - Natalie specializes in assessing the scientific validity of investment opportunities.
Shikin Gani, Executive Assistant - Shikin supports the team with administrative tasks and coordination.
Jack Shea-Firth PhD, Investment Analyst - Jack analyzes potential investments and conducts market research.
Owen Smith CPFA, Partner - Owen has extensive experience in financial management and investment strategy.
To pitch to 4BIO Capital, founders should send an email to info@4biocapital.com. It is important to include a comprehensive overview of the business, the problem being addressed, and the proposed solution. A well-structured pitch deck that outlines the market opportunity and the team's qualifications is recommended.
4BIO Capital has been active in the investment landscape, with notable portfolio developments. Recently, Araris Biotech announced its acquisition by Taiho Pharmaceutical for up to USD 1.14 billion, showcasing the potential of its innovative therapies. Additionally, Trogenix secured £70 million in Series A financing to advance its clinical development for aggressive cancers.
These events highlight 4BIO Capital's commitment to supporting companies that are addressing high unmet medical needs through advanced therapies.
What are 4BIO Capital's investment criteria?
4BIO Capital invests in early-stage companies within the advanced therapies sector, focusing on cell therapy, gene therapy, RNA-based therapy, targeted therapies, and microbiome-related treatments. The firm seeks opportunities that address significant medical and social needs.
How can I apply or pitch to 4BIO Capital?
Founders can pitch to 4BIO Capital by sending an email to info@4biocapital.com. It is advisable to include a detailed overview of the business, the problem being addressed, and the proposed solution in the pitch.
What makes 4BIO Capital different from other venture capital firms?
4BIO Capital's distinct focus on advanced therapies and its commitment to addressing high unmet medical needs set it apart. The firm combines expertise in medicine, finance, and academia to support innovative healthcare solutions.
What is the geographic scope of 4BIO Capital's investments?
The firm primarily invests in Europe and the United Kingdom, targeting early-stage companies that operate within these regions.
What is 4BIO Capital's post-investment involvement like?
4BIO Capital actively supports its portfolio companies through mentorship, operational guidance, and access to its network of industry experts. The firm aims to enhance the growth potential of its investments.
What is the typical check size for investments?
While specific check sizes are not disclosed, 4BIO Capital focuses on pre-seed, seed, and seed-plus stages, indicating that investments are likely tailored to the needs of early-stage companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.